Jump to content

Senolytics: Difference between revisions

642 bytes removed ,  31 December 2023
Line 13: Line 13:


* 2019: Scientists at the Mayo Clinic report the first successful use of [[Senolytics|senolytics]], a new class of drug with potential anti-aging benefits, to remove [[Senescent Cells|senescent cells]] from human patients with a kidney disease.
* 2019: Scientists at the Mayo Clinic report the first successful use of [[Senolytics|senolytics]], a new class of drug with potential anti-aging benefits, to remove [[Senescent Cells|senescent cells]] from human patients with a kidney disease.
<ref>{{cite web|url=https://newsnetwork.mayoclinic.org/discussion/mayo-researchers-demonstrate-senescent-cell-burden-is-reduced-in-humans-by-senolytic-drugs/|title=Mayo researchers demonstrate senescent cell burden is reduced in humans by senolytic drugs|work=Mayo Clinic|date=18 September 2019|access-date=20 September 2019}}</ref><ref>{{cite web|url=https://www.ebiomedicine.com/article/S2352-3964(19)30591-2/pdf|title=Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease|work=EBioMedicine|date=20 September 2019|access-date=20 September 2019}}</ref>
{{pmid|31542391}}
* 2021: Scientists report alternative approach to [[Senolytics|senolytics]] for removing [[Senescent Cells|senescent cells]]: invariant NKT (iNKT) cells.<ref>{{cite news|title=Scientists find mechanism that eliminates senescent cells|url=https://medicalxpress.com/news/2021-05-scientists-mechanism-senescent-cells.html|access-date=28 June 2021|work=medicalxpress.com|language=en}}</ref><ref>{{cite journal|vauthors=Arora S, Thompson PJ, Wang Y, Bhattacharyya A, Apostolopoulou H, Hatano R, Naikawadi RP, Shah A, Wolters PJ, Koliwad S, Bhattacharya M, Bhushan A|display-authors=6|title=Invariant Natural Killer T cells coordinate removal of senescent cells|language=English|journal=Med|volume=2|issue=8|pages=938–950|date=August 2021|pmid=34617070|pmc=8491998|doi=10.1016/j.medj.2021.04.014|doi-access=free}}</ref>
* 2021: Scientists report alternative approach to [[Senolytics|senolytics]] for removing [[Senescent Cells|senescent cells]]: invariant NKT (iNKT) cells.<ref>{{cite news|title=Scientists find mechanism that eliminates senescent cells|url=https://medicalxpress.com/news/2021-05-scientists-mechanism-senescent-cells.html|access-date=28 June 2021|work=medicalxpress.com|language=en}}</ref><ref>{{cite journal|vauthors=Arora S, Thompson PJ, Wang Y, Bhattacharyya A, Apostolopoulou H, Hatano R, Naikawadi RP, Shah A, Wolters PJ, Koliwad S, Bhattacharya M, Bhushan A|display-authors=6|title=Invariant Natural Killer T cells coordinate removal of senescent cells|language=English|journal=Med|volume=2|issue=8|pages=938–950|date=August 2021|pmid=34617070|pmc=8491998|doi=10.1016/j.medj.2021.04.014|doi-access=free}}</ref>
* 2022: [[Biogerontology|Biomedical gerontologists]] demonstrate a mechanism of anti-aging senolytics, in particular of [[Dasatinib]] plus [[Quercetin]] (D+Q) – an increase of α-Klotho as shown in mice, human cells and in a human trial.<ref>{{cite news|title=Senolytic drugs boost key protective protein|url=https://newsnetwork.mayoclinic.org/discussion/senolytic-drugs-boost-key-protective-protein/|access-date=19 April 2022|work=Mayo Clinic News Network|date=15 March 2022}}</ref>{{pmid|35292270}}
* 2022: [[Biogerontology|Biomedical gerontologists]] demonstrate a mechanism of anti-aging senolytics, in particular of [[Dasatinib]] plus [[Quercetin]] (D+Q) – an increase of α-Klotho as shown in mice, human cells and in a human trial.<ref>{{cite news|title=Senolytic drugs boost key protective protein|url=https://newsnetwork.mayoclinic.org/discussion/senolytic-drugs-boost-key-protective-protein/|access-date=19 April 2022|work=Mayo Clinic News Network|date=15 March 2022}}</ref>{{pmid|35292270}}
Cookies help us deliver our services. By using our services, you agree to our use of cookies.